A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Overview of attention for article published in SpringerPlus, August 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet

twitter: 4 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 28 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

interferon combo regimen for hcv gt23

HCP Live, 22 Aug 2016

Peginterferon Lambda-1a plus ribavirin (Lambda/RBV) may be a better treatment for chronic hepatitis C virus (HCV) genotype 2 or…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.